

RESEARCH ARTICLE

Open Access

# Multiplex genomic structure variation mediated by TALEN and ssODN

Sanyuan Ma<sup>1</sup>, Xiaogang Wang<sup>1</sup>, Yuanyuan Liu<sup>1</sup>, Jie Gao<sup>1</sup>, Shengling Zhang<sup>1</sup>, Run Shi<sup>1</sup>, Jiasong Chang<sup>1</sup>, Ping Zhao<sup>1</sup> and Qingyou Xia<sup>1,2\*</sup>

## Abstract

**Background:** Genomic structure variation (GSV) is widely distributed in various organisms and is an important contributor to human diversity and disease susceptibility. Efficient approaches to induce targeted genomic structure variation are crucial for both analytic and therapeutic studies of GSV. Here, we presented an efficient strategy to induce targeted GSV including chromosomal deletions, duplications and inversions in a precise manner.

**Results:** Utilizing Transcription Activator-Like Effector Nucleases (TALEN) designed to target two distinct sites, we demonstrated targeted deletions, duplications and inversions of an 8.9 Mb chromosomal segment, which is about one third of the entire chromosome. We developed a novel method by combining TALEN-induced GSV and single stranded oligodeoxynucleotide (ssODN) mediated gene modifications to reduce unwanted mutations occurring during the targeted GSV using TALEN or Zinc finger nuclease (ZFN). Furthermore, we showed that co-introduction of TALEN and ssODN generated unwanted complex structure variation other than the expected chromosomal deletion.

**Conclusions:** We demonstrated the ability of TALEN to induce targeted GSV and provided an efficient strategy to perform GSV precisely. Furthermore, it is the first time to show that co-introduction of TALEN and ssODN generated unwanted complex structure variation. It is plausible to believe that the strategies developed in this study can be applied to other organisms, and will help understand the biological roles of GSV and therapeutic applications of TALEN and ssODN.

**Keywords:** TAL Effectors, Genomic structure variation, Chromosomal deletion, Chromosomal duplication, Chromosomal inversion, ssODN

## Background

Genomic structure variations (GSVs), including chromosomal deletions, duplications, inversions, insertions and translocations, are one of the most important contributors to genetic diversity and often associated with diseases and cancers [1-5]. To reveal the landscape of genetic variation in human or various organisms, several methods including next-generation sequencing and paired-end mapping have been developed to detect and characterise GSV [6]. However, the relationship between GSV and phenotypic consequence remains unclear. Efficient approaches to induce targeted GSV are crucial for studying this relationship and for practicing personalized gene therapy. Approaches

to generate targeted translocations [7,8], deletions [5], or duplications and inversions [5] of genomic segments in human cells have been developed by generating two double strand breaks (DSB) utilizing two pairs of engineered ZFN. But the outcomes of induced GSV in a population varied greatly among the progeny, suggested that the non-homologous end joining (NHEJ) repair of ZFN induced DSB would produce multiple, unpredicted mutations. Therefore, induction of GSV directly using this strategy is undesirable in fundamental studies and risky in gene therapy. Oligonucleotide-based gene modification is a site specific genome editing strategy utilizing triplex-forming oligonucleotide or single-stranded oligodeoxynucleotide and has been shown to successfully mediate modification of genomic DNA in mammalian cells in a precise sequence-specific manner [9], but with much lower efficiency.

Generally, it is challenging to generate custom ZFNs with high specificity and activity from non-commercial

\* Correspondence: xiaqy@swu.edu.cn

<sup>1</sup>State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing, China

<sup>2</sup>Present Address: State Key Laboratory of Silkworm Genome Biology, Southwest University, Beibei, Chongqing 400716, China

sources. TALENs, a recently developed genome editing method, has proved to be a more accessible genetic manipulation tool since TALENs can readily be manufactured in academic research labs with common existing molecular biology reagents and expertise [10]. We previously showed that two pairs of TALENs could also induce a heritable 792 bp chromosomal deletion in silkworm, *Bombyx mori*, in a similar manner of ZFN in human cell lines [11]. Targeted 7 kb deletions and inversions using TALEN were also demonstrated in livestock [12]. These studies suggested that TALEN can serve as a more powerful tool to induce targeted GSV. Also, various strategies to construct custom TALEN have been established, including standard restriction enzyme and ligation-based cloning, 'Golden Gate' cloning, solid-phase assembly and ligation independent cloning technique for both single TALEN construction and high throughput assembly [13-15]. Generating an active TALEN pair is feasible for any researcher who is familiar with conventional molecular cloning. We proposed that a combination of TALEN induced DSB and Oligonucleotide-based gene modification induce targeted GSV in a predictable, precise sequence specific manner.

To verify our hypothesis, we constructed an active TALEN targeted to an endogenous gene (*Bm702*), which is 8.9 Mb downstream *BmBlos2* and induced targeted GSV in silkworm embryos. Our results revealed that: (1) simultaneous expression of two TALENs could induce targeted genomic deletions, inversions and duplications, and (2) addition of ssODN could reduce unwanted mutations. In addition, delivery of additional TALEN into the organism may increase the possibility of off-target cleavage, which is the major concern of hybrid nucleases mediated genome editing. We also tested the possibility of chromosomal deletions using one pair of TALEN together with an ssODN.

## Results



### High genome editing activity of TALEN-702 *in vivo*

Previously we have constructed two active TALENs targeting the 2<sup>nd</sup> exon and the 3<sup>rd</sup> exon of *BmBlos2*, termed TALEN-B2 and TALEN-B3 in this study. The results showed that simultaneous expression in silkworm embryos could generate heritable 792 bp chromosome deletions [11]. To test whether TALEN can induce GSV such as genomic deletions, inversions and duplications with a large chromosomal fragment, we selected *Bm702*, an endogenous gene located 8.9 Mb downstream of *BmBlos2* as a target gene to generate additional TALEN (Figure 1a). To test the activity of TALEN-702, a 48 bp recognition site was cloned into the pSSA-Luc vector. The insertion site was between two truncated luciferase fragments. The vector was transfected into human embryonic kidney (HEK) 293 T cells with or without transcribed TALEN-702 mRNA *in vitro*. Luciferase activity of co-transfection of

TALEN-702 and SSA reporter vector detected 24 h post-transfection showed a 28-fold increase, compared with transfection of SSA reporter vector only (Figure 2A), which suggested that TALEN-702 has a high activity to promote homologous recombination (HR) events in HEK 293 T cells. As SSA recombination assay is based on the HR repair pathway, and targeted GSV relies on the NHEJ repair pathway, T7 Endonuclease I digestion (T7EI) assay was then conducted to demonstrate that the repair of TALEN-induced DSB was through the NHEJ repair pathway. TALEN-702 mRNA was microinjected into about 100 silkworm embryos. To detect NHEJ events, PCR product using primers flanking the endogenous TALEN-702 cleavage site (702 F-883 and 702R-611, Additional file 1: Table S2) was subjected to T7 Endonuclease I digestion. The length from forward and reverse primer to TALEN-702 cleavage site is 883 and 611 bp, respectively, so the PCR product can be digested into two fragments (883 and 611 bp) only if NHEJ events occur at TALEN-702 cleavage site. The result showed that TALEN-702 could induce efficient mutations in the endogenous gene loci through NHEJ repair pathway (Figure 2B). However, the accurate mutation frequency can not be measured because of the existence of SNP bands (about 1000 and 500 bp, Figure 2B).


### Large chromosomal structure variation mediated by TALEN-B2 and TALEN-702

Previously we have shown that co-expression of TALEN-B2 and TALEN-B3 could induce a heritable 792 bp chromosomal deletion [11]. To test whether such deletion can occur between two DSBs whose distance is much larger, and whether co-expression of two distant TALENs can induce chromosomal inversions and duplications, *in vitro* transcribed mRNA of TALEN-B2 and TALEN-702 were mixed and microinjected into about 100 silkworm embryos. PCR was performed using genomic DNA from pooled embryos 3 day after microinjection and specific primers to detect genomic deletions, duplications and inversions. As shown in Figure 3, all primers designed to detect 8.9 Mb deletions, duplications and inversions could amplify products with expected size from genomic DNA of injected embryos (Figure 3B), but not un-injected (Figure 3A). Compared with bands of native locus, bands of induced GSV products are much weaker, but they still can be detected easily at various PCR conditions (data not shown), indicating a considerable frequency. To further confirm the targeted GSV, we cloned the PCR products and determined their sequences. The results showed that 5' portion of the 2<sup>nd</sup> exon of *BmBlos2* was directly joined to 3' portion of the 2<sup>nd</sup> exon of *Bm702* in the deletion events; 5' portion of the 2<sup>nd</sup> exon of *Bm702* was directly joined to 3' portion of the 2<sup>nd</sup> exon of *BmBlos2* in duplication events; 5' portion of the 2<sup>nd</sup> exon of *BmBlos2* were joined to inverted 5' portion of the 2<sup>nd</sup>









within every genome, and are likely to make an important contribution to human diversity and disease susceptibility [19]. As the rapid progress of genome sequencing and bioinformatics tools, GSV has been identified in more and more genomes of various organisms including animals and plants. Targeted induction of certain GSV such as deletion, duplication and inversion is one of the most important tasks of genome editing for both analytic and therapeutic purposes. Compared with conventional gene targeting such as site directed mutagenesis (knockout), gene correction and addition, targeted GSV can be used to reveal the relationship between natural occurred GSV and its phenotypic impact, and to be used as powerful genetic manipulation tools to reengineer large chromosomal segments such as regulatory elements, non-coding RNAs and transgenes.

In recent years, genetic manipulation was greatly revolutionized as the emergence of ZFN and TALEN, as well as the newly emerged RNA-mediated genome editing tools [20-22]. It is much easier and faster to generate site specific knock-out organisms for both model and non-model

systems. At the same time, the ability to induce targeted GSV has also been demonstrated in human cells [5,9,23,24] and in tobacco [25] using two pairs of ZFN, in human cells using a pair of ZFN together with ssODN [17], in silkworm and live stock using two pairs of TALEN [11,12] and in zebrafish using ZFN and TALEN [26]. However, more evidences are needed to address the questions raised by these pioneered studies and those uncovered issues.

Although ZFN and TALEN contain the same *FokI* nuclease domain and function in a similar way to induce mutations, it was observed that ZFN and TALEN were associated with different mutation patterns [11,27]. Successful targeted chromosomal deletions, duplications and inversions using ZFN [5,9,23-25] prompt us to investigate the possibility of targeted GSV using TALEN. We have previously shown that simultaneous expression of two TALENs could mediate heritable 792 bp segment deletion in silkworm, *B. mori* [11], which was also supported by similar investigations in livestock [12] and zebrafish [26]. In the present study, we generated an active TALEN targeting to an endogenous gene, *Bm702*, which is about

8.9 Mb downstream *BmBlos2* (Figure 1a). Utilizing these two TALENs, we demonstrated that chromosomal deletions and inversions could be obtained at a considerable frequency, and targeted chromosomal duplications were also detected, which was not demonstrated before using TALEN. As there are too many genes in the 8.9 Mb region, it is nearly impossible for us to detect whether these modifications are heritable. However, the observed mutation efficiency should be high enough to generate heritable mutations according to our experience in silkworm. Our results in the present study, together with those reported previously [11,12,26], provided an alternative or even better tool for targeted GSV. To reduce unwanted mutations in the targeted GSV outcomes, which are unexpected in both fundamental studies and therapeutic applications, we combined the TALEN-induced GSV and ssODN mediated gene modifications. Despite the fact that not 100% of the mutant sequences were expected, TALEN-induced GSV was observed to work in a more precise manner after introduction of well designed ssODN.

Although at a very low efficiency, it is encouraging to observe targeted chromosomal deletion using TALEN-B3 and B3-794 in somatic cell of silkworm, suggesting that this strategy can also work with TALEN. Unfortunately, none of the five heritable mutants showed the expected genotype. Instead, two of them were mutants generated by TALEN-B3 only and the other three exhibit abnormal chromosomal rearrangements. We speculate that the difference between precise chromosomal deletion demonstrated in human cells [17] and unpredictable outcomes observed in our studies might due to the following reasons. (1) Compared with 5 or 6 bp spacers of ZFN, TALEN-B3 has a much larger size of spacer (16 bp). Generally, larger spacers are easier to generate heterogeneous overhangs than the well defined 4- or 5-bp overhangs produced by ZFN [28]. It is demonstrated that defined overhangs may facilitate targeted insertions of plasmid DNA at genomic sites [29]. (2) Neither ZFN nor TALEN was demonstrated to work with ssODN to generate precise large chromosomal deletions in organisms other than human cell lines. It is possible but not probable that this mechanism doesn't work in insect species and perhaps other organisms. However, further investigations are needed to demonstrate the above possibilities. This finding also raises a concern about gene therapy, that hybrid nucleases and ssODN, both of which are thought to be or have been used in gene therapy [30,31], may induce unwanted chromosomal changes.

## Conclusion

In summary, we demonstrated the ability of 2 pairs of TALEN to induce GSV including deletion, duplication and inversion of a chromosomal fragment as large as 8.9 Mb, which is about one third of the entire chromosome, and developed an efficient strategy to reduce the

unwanted mutations during structure variation by adding ssODN. Furthermore, it is the first time to show in this study that co-introduction of one pair of TALEN and ssODN may generate complex structure changes other than the expected chromosomal deletion. Although most of the experiments were conducted in silkworm, *B. mori*, a research model Lepidoptera insect, the DNA repair pathways that contend with DNA damage are highly conserved in all living organisms [32,33], and the mechanism of TALEN-induced mutation is thought to be identical in different biological systems. Thus it is plausible to believe that the strategies developed in this study can be applied to other organisms, and will help understand the biological roles of GSV and therapeutic applications of TALEN.

## Methods

### Design and construction of TALEN-702

The sequence of the 2<sup>nd</sup> exon of *Bm702* was subjected to a web-based designer tool (<http://zifit.partners.org/ZiFiT/Disclaimer.aspx>) to design the target site. To avoid potential off-target cleavage, potential sites were aligned to silkworm genome sequence to remove those sequence with homologous in the genome. A 48 bp target sequence was selected, and the corresponding TALEN sequence (TALEN-702 L and TALEN-702R) were generated using backbone as described previously [11] and repeat variable di-residue (RVD) following the rules that NG, HD, NI, and NN recognize T, C, A, and G, respectively (Figure 1b and c). The assembly of TAL effector domain was completed through a commercial service (ViewSolid Biotech).

### mRNA synthesis

Plasmid vectors TALEN-702 L and TALEN-702R were prepared using a plasmid midi kit (QiaGen), digested with *XbaI* (NEB) and phenol/chloroform purified. *in vitro* transcription was performed using MessageMax™ T7 ARCA-capped Message Transcription Kit (Epicentre Biotechnologies). Cap RNA was then polyadenylated using the Poly (A) Polymerase Tailing Kit (Epicentre Biotechnologies). The resulting mRNA was purified using the MegaClear Kit (Ambion) and quantified using a NanoDrop-2000 (Thermo Scientific). mRNA was dissolved in RNase-free water (Sigma-Aldrich) to a concentration of 500 ng/μl. TALEN-702 L and TALEN-702R mRNA were mixed at a molar ratio of 1:1 and stored at -80°C.

### Luciferase single-strand annealing (SSA) reporter gene assay

The luciferase SSA assay was performed as described elsewhere [15]. The template plasmid containing TALEN-702 target site was generated by PCR-based mutagenesis using a primer containing 48 bp target site at the 5' portion. The HEK 293 T cell line, which is widely used as an *in vitro* model system for transfection

experiments, was provided by Dr. Fengfeng Zhuang from View-solid Biotech. The use of HEK 293 T cell line was approved by the institutional Ethics Committees of our university and conducted in accordance with the ethical guidelines of the Declaration of Helsinki.

### Microinjection of silkworm embryos

A diapausing strain, Dazao, which is widely used as a wild type silkworm, was utilized in this study. The larvae were reared with fresh mulberry leaves at 25°C, 75% RH. Parental embryos (P) were incubated at 15°C and 75% RH to produce nondiapausing eggs (G0), which are suitable for microinjection. The microinjections were performed utilizing TransferMan NK2 micromanipulator and Femto Jet 5247 microinjector (Eppendorf) under an SZX16 microscope (Olympus) as we reported previously [11]. For transient assays, embryos were injected within 5 hours after oviposition and harvested 3 days post injections. For germline assays such as heritable chromosomal deletion using TALEN-B3 and ssODN B3-794, embryos were injected within 2 hours after oviposition and allowed to develop to moths. Mosaic mutations were observed as early as the 3<sup>rd</sup> instar. The resulting G0 males were first crossed with G0 females and the remaining uncopulated G0 males were crossed with wild-type females. The G1 mutations were checked for the translucent skin phenotype on the 3<sup>rd</sup> instar, and all the positive mutations were allowed to develop to the moths.

### T7 endonuclease I assay

*In vitro* transcribed TALEN-702 mRNA were microinjected into about 100 silkworm embryos. Genomic DNA was extracted from injected embryos using standard phenol/chloroform method. The genomic region encompassing TALEN-702 target site was amplified using primers 702-F883 and 702-R611 (Table S2). The PCR product was treated 5 units of T7 endonuclease 1 (NEB) for 15 min at 37°C and then precipitated by addition of 2.5 volumes of ethanol. The precipitated DNA was analyzed by agarose gel electrophoresis. Genomic DNA from un-injected embryos was used as control.

### Design and synthesis of ssODN

The ssODN was designed as described by Chen *et al.* [17] and synthesized using a commercial service (Genescript). The ssODN was dissolved in RNase-free water (Sigma-Aldrich) at 100 mM and mixed with corresponding TALEN mRNA for microinjection.

### Sequencing of the mutations

PCR products were inserted into a T-vector (TransGen) and sequenced using a commercial service (Beijing Genomics Institute). The methods used for PCR and T-cloning

were followed standard molecular cloning protocols and the instructions provided by the manufacturers.

### Additional file

**Additional file 1: Figure S1.** Chromosomal deletions using TALEN-B3 and B3-794. M represents the DNA ladders, the letters on the left indicate length of each band. The numbers at the top of each panel represent the silkworm hatched from embryos injected with B3 mRNA and ssODN. The main band is from the native BmBlos2 locus with or without the B3-induced small modifications. The expected bands were about 556 bp if large deletions occurred. The numbers at the bottom represent the relative frequencies of large deletions. **Table S1.** Microinjection of TALEN and ssODN into the embryo of Dazao. **Table S2.** Primers and oligodeoxynucleotides used in this study.

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

SYM and QYX conceived the study. SYM, XGW, YYL, PZ and QYX designed and analyzed all the experiments. JG, RS and JSC performed the cloning and sequencing. SYM and QYX wrote the manuscript with support from all authors. All authors read and approved the final manuscript.

### Acknowledgment

The authors would like to thank Dr. Fengfeng Zhuang for the support of SSA experiment, Dr. Huawei He and Yi Zhang for valuable and critical comments on the manuscript, and Dr. Ying Lin for the support of silkworm rearing. This work was supported by the Chinese Ministry of Science and Technology [2012CB114600, 2011AA100306]; and the doctoral Innovation Fund of Southwest University [kb2010002].

Received: 22 September 2013 Accepted: 13 January 2014

Published: 18 January 2014

### References

1. Korbel J, Urban A, Affourtit J, Godwin B, Grubert F, Simons J, Kim P, Palejev D, Carriero N, Du L, Taillon BE, Chen Z, Tanzer A, Saunders AC, Chi J, Yang F, Carter NP, Hurler ME, Weissman SM, Harkins TT, Gerstein MB, Egholm M, Snyder M: **Paired-end mapping reveals extensive structural variation in the human genome.** *Science* 2007, **318**:420–426.
2. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, González JR, Gratacòs M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, Tchiinda J, Valsesia A, Woodwark C, Yang F, *et al*: **Global variation in copy number in the human genome.** *Nature* 2006, **444**:444–454.
3. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE, Foekens JA, Reis-Filho JS, Vant Veer L, Richardson AL, Børresen-Dale AL, *et al*: **Complex landscapes of somatic rearrangement in human breast cancer genomes.** *Nature* 2009, **462**:1005–1010.
4. Stankiewicz P, Lupski JR: **Structural variation in the human genome and its role in disease.** *Annu Rev Med* 2010, **61**:437–455.
5. Lee HJ, Kweon J, Kim E, Kim S, Kim JS: **Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases.** *Genome Res* 2011, **22**:539–548.
6. Chen K, Wallis JW, McLellan MD, Larson DE, Kalicki JM, Pohl CS, McGrath SD, Wendl MC, Zhang Q, Locke DP, Shi X, Fulton RS, Ley TJ, Wilson RK, Ding L, Mardis ER: **BreakDancer: An algorithm for high-resolution mapping of genomic structural variation.** *Nat Methods* 2009, **6**:677–681.
7. Brunet E, Simsek D, Tomishima M, DeKelver R, Choi VM, Gregory P, Urnov F, Weinstock DM, Jasin M: **Chromosomal translocations induced at specified loci in human stem cells.** *Proc Natl Acad Sci U S A* 2009, **106**:10620–10625.
8. Simsek D, Brunet E, Wong SY, Katyal S, Gao Y, McKinnon PJ, Lou J, Zhang L, Li J, Rebar EJ, Gregory PD, Holmes MC, Jasin M: **DNA ligase III promotes**



- alternative nonhomologous end-joining during chromosomal translocation formation. *PLoS Genet* 2011, **7**:e1002080.
9. Sargent RG, Kim S, Gruenert DC: **Oligo/polynucleotide-based gene modification: strategies and therapeutic potential.** *Oligonucleotides* 2011, **21**:55–75.
  10. Joung JH, Sander JD: **TALENs: a widely applicable technology for targeted genome editing.** *Nat Rev Mol Cell Biol* 2013, **14**:49–55.
  11. Ma S, Zhang S, Wang F, Liu Y, Liu Y, Xu H, Liu C, Lin Y, Zhao P, Xia Q: **Highly efficient and specific genome editing in silkworm using custom TALENs.** *PLoS ONE* 2012, **7**(9):e45035.
  12. Carlson DF, Tan W, Lillico SG, Stverakova D, Proudfoot C, Christian M, Voytas DF, Long CR, Whitelaw CB, Fahrenkrug SC: **Efficient TALEN-mediated gene knockout in livestock.** *Proc Natl Acad Sci U S A* 2012, **109**:17382–17387.
  13. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK: **FLASH assembly of TALENs for high-throughput genome editing.** *Nat Biotechnol* 2012, **30**:460–465.
  14. Schmid-Burgk JL, Schmidt T, Kaiser V, Höning K, Hornung V: **A ligation-independent cloning technique for high-throughput assembly of transcription activator-like effector genes.** *Nat Biotechnol* 2012, **31**(1):76–81.
  15. Wang Z, Li J, Huang H, Wang G, Jiang M, Yin S, Sun C, Zhang H, Zhuang F, Xi JJ: **An integrated chip for the high-throughput synthesis of transcription activator-like effectors.** *Angew Chem Int Ed Engl* 2012, **51**:8505–8508.
  16. Tesson L, Usal C, Ménoret S, Leung E, Niles BJ, Remy S, Santiago Y, Vincent AI, Meng X, Zhang L, Gregory PD, Anegón I, Cost GJ: **Knockout rats generated by embryo microinjection of TALENs.** *Nat Biotechnol* 2011, **29**(8):695–696.
  17. Chen F, Pruett-Miller SM, Huang Y, Gjoka M, Duda K, Taunton J, Collingwood TN, Frodin M, Davis GD: **High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases.** *Nat Methods* 2011, **8**:753–755.
  18. Sharp AJ, Cheng Z, Eichler EE: **Structural variation of the human genome.** *Annu Rev Genomics Hum Genet* 2006, **7**:407–442.
  19. Feuk L, Carson AR, Scherer SW: **Structural variation in the human genome.** *Nat Rev Genet* 2006, **7**(2):85–97.
  20. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F: **Multiplex genome engineering using CRISPR/Cas systems.** *Science* 2013, **339**(6121):819–823.
  21. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM: **RNA-guided human genome engineering via Cas9.** *Science* 2013, **339**(6121):823–826.
  22. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J: **RNA-programmed genome editing in human cells.** *Elife* 2013, **2**:e00471.
  23. Söllü C, Pars K, Cornu TI, Thibodeau-Beganny S, Maeder ML, Joung JK, Heilbronn R, Cathomen T: **Autonomous zinc-finger nuclease pairs for targeted chromosomal deletion.** *Nucleic Acids Res* 2010, **38**(22):8269–8276.
  24. Lee HJ, Kim E, Kim JS: **Targeted chromosomal deletions in human cells using zinc finger nucleases.** *Genome Res* 2010, **20**:81–89.
  25. Petolino JF, Worden A, Curlee K, Connell J, Strange Moynahan TL, Larsen C, Russell S: **Zinc finger nuclease-mediated transgene deletion.** *Plant Mol Biol* 2010, **73**(6):617–628.
  26. Gupta A, Hall VL, Kok FO, Shin M, McNulty JC, Lawson ND, Wolfe SA: **Targeted chromosomal deletions and inversions in Zebrafish.** *Genome Res* 2013, **23**(6):1008–1017.
  27. Kim Y, Kweon J, Kim JS: **TALENs and ZFNs are associated with different mutation signatures.** *Nat Methods* 2013, **10**(3):185.
  28. Orlando SJ, Santiago Y, DeKaveler RC, Freyvert Y, Boydston EA, Moehle EA, Choi VM, Gopalan SM, Lou JF, Li J, Miller JC, Holmes MC, Gregory PD, Urnov FD, Cost GJ: **Zinc-finger nuclease-driven targeted integration into mammalian genomes using donors with limited chromosomal homology.** *Nucleic Acids Res* 2010, **38**(15):e152.
  29. Maresca M, Lin VG, Guo N, Yang Y: **Obligate Ligation-Gated Recombination (ObLiGaRe): Custom-designed nucleases mediated targeted integration through nonhomologous end joining.** *Genome Res* 2013, **23**(3):539–546.
  30. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM: **Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 *in vivo*.** *Nat Biotechnol* 2010, **28**:839–847.
  31. Aarts M, te Riele H: **Progress and prospects: oligonucleotide-directed gene modification in mouse embryonic stem cells: a route to therapeutic application.** *Gene Ther* 2011, **18**(3):213–219.
  32. Taylor EM, Lehmann AR: **Conservation of eukaryotic DNA repair mechanisms.** *Int J Radiat Biol* 1998, **74**(3):277–286.
  33. Cromie GA, Connelly JC, Leach DR: **Recombination at double-strand breaks and DNA ends: conserved mechanisms from phage to humans.** *Mol Cell* 2001, **8**(6):1163–1174.

doi:10.1186/1471-2164-15-41

Cite this article as: Ma et al.: Multiplex genomic structure variation mediated by TALEN and ssODN. *BMC Genomics* 2014 15:41.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

